Clinical Trial NCT05744921
Trial
Regeneron – 2050 2021-004931-10 (NCT05744921)
Clinical trial ID
NCT05744921
Drug name
Pozelimab and Cemdisiran
Company:
Regeneron
Drug trade name
---
Clinicaltrials.gov
Learn more
Phase of study
3
Current status
Recruiting
Start
03/2023
Substance
Monoclonal antibody and RNAi
Research question
Safety, efficacy and tolerability of combination therapy
Delivery method of drug
s.c.
Frequency
Every four weeks
Clinical trial locations
Korea